Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07420374

Ambulatory Stroke Unit Treatment for Elderly Patients

ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.

Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).

Secondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Stroke unit treatment in Germany is currently organized as multi-day inpatient care regardless of stroke severity. However, a substantial proportion of patients with acute ischemic stroke or transient ischemic attack present with non-disabling or fully regressed neurological deficits and may not require prolonged inpatient monitoring. At the same time, demographic changes and increasing stroke incidence in older populations challenge inpatient stroke unit capacity and resource allocation.

International experience with structured outpatient TIA and minor stroke clinics suggests that ambulatory management models may provide comparable clinical safety while reducing hospital utilization. However, randomized evidence for such models within the German healthcare system is lacking.

The ARTIFICE trial evaluates a structured ambulatory stroke unit care model designed to provide comprehensive same-day multiprofessional assessment and initiation of secondary prevention while maintaining patient safety. The study investigates whether this ambulatory care approach can represent a medically safe and resource-efficient alternative to conventional inpatient stroke unit treatment in selected older patients.

In addition to clinical effectiveness, the study examines patient-reported outcomes, healthcare utilization, cost-effectiveness, and implementation aspects to inform future health services planning.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 60 years
  • Diagnosis of acute ischemic stroke (ICD-10 I63.), transient ischemic attack (G45.), or retinal ischemia (H34.*)
  • Symptom onset ≤ 7 days before enrollment
  • No or non-disabling newly occurring neurological deficit allowing safe ambulatory management
  • Written informed consent provided by the participant or, if lacking decision-making capacity, by a legally authorized representative

Exclusion criteria

  • Requirement for urgent surgical or interventional secondary prevention (e.g., carotid revascularization)
  • Fluctuating stroke symptoms within the previous 48 hours
  • Acute febrile infection or isolation-requiring infectious disease
  • Clinically relevant dysphagia with high aspiration risk
  • Critical medical or nursing findings requiring mandatory multi-day inpatient treatment
  • Palliative care situation with limitation of acute diagnostic or therapeutic measures
  • Previous participation in the ambulatory stroke unit care model
  • No statutory health insurance coverage in Germany
  • Insufficient German language proficiency to understand study procedures and assessments

Treatment and study plan

Ambulatory Stroke Unit Care

Other

Structured ambulatory stroke care model providing same-day neurological assessment, diagnostic work-up, therapeutic evaluation, and multidisciplinary case review, followed by discharge home if medically appropriate.

Conventional Stroke Unit Care

Other

Standard inpatient stroke unit treatment according to national clinical guidelines, including hospital-based monitoring, diagnostic evaluation, and initiation of secondary prevention.

Primary outcomes

  1. Favorable Functional Outcome at 90 Days

    Time frame: 90 days (±14 days) after randomization

    Favorable functional outcome defined as modified Rankin Scale (mRS) score 0-2 or return to pre-stroke mRS level, assessed by blinded outcome assessors.

Secondary outcomes

  1. Early Neurological Deterioration

    Time frame: Within 7 days after randomization

    Increase in National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points compared to baseline.

  2. Recurrent Stroke

    Time frame: Up to 90 days after randomization (primary safety observation period)

    Occurrence of recurrent ischemic stroke, hemorrhagic stroke, or transient ischemic attack during follow-up.

  3. Delirium Occurrence

    Time frame: Within 7 days after randomization

    Occurrence of delirium assessed using the Confusion Assessment Method (CAM).

  4. All-Cause Mortality

    Time frame: 90 days and 12 months after randomization

    Death from any cause.

  5. Functional Status

    Time frame: Baseline and 90 days

    Change in Barthel Index score from baseline to 90 days.

  6. Stroke Impact

    Time frame: Baseline and 90 days

    Change in SIS-16 score from baseline to 90 days.

  7. Mobility

    Time frame: Baseline and 90 days

    Change in Timed Up and Go Test (TUG) time from baseline to 90 days.

  8. Health-Related Quality of Life

    Time frame: Baseline and 90 days

    Change in EQ-5D-5L index value and EQ visual analogue scale (EQ-VAS) from baseline to 90 days.

  9. Healthcare Utilization

    Time frame: Up to 90 days after randomization

    Use of outpatient, inpatient, and nursing care services assessed by questionnaire.

  10. Serious Adverse Events

    Time frame: Up to 90 days after randomization

    Occurrence of serious adverse events including unplanned hospitalization or death.

Study contacts

Contact information is provided by the study sponsor or research team.

Jan C Purrucker, Prof. Dr.

CONTACT

[email protected]

+49 6221 56 6999

Sponsors and collaborators

Lead sponsor

University Hospital Heidelberg

Other

Collaborators

  • Heinrich-Heine University, Duesseldorf
  • inav - Institute for Applied Health Services Research GmbH, Berlin, Germany

Registry information

Official study title

Ambulatory Stroke Unit Treatment for Elderly Patients: A Prospective, Randomized, Controlled, Exploratory Non-Inferiority Trial (ARTIFICE)

Acronym: ARTIFICE

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 19, 2026
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.